If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research Interests

Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Clinical trials

Training Experience

1995Internship, Mount Sinai Hospital, New York
1996Residency, Mount Sinai Hospital, New York

Education/Academic qualification

MD, University La Sapienza, Rome, Italy

… → 1988

Research interests

  • Blood Cancer (leukemia and lymphomas)
  • Clinical Research

Fingerprint Dive into the research topics where Barbara Pro is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 15 Similar Profiles
Peripheral T-Cell Lymphoma Medicine & Life Sciences
Non-Hodgkin's Lymphoma Medicine & Life Sciences
Lymphoma Medicine & Life Sciences
Hodgkin Disease Medicine & Life Sciences
T-Cell Lymphoma Medicine & Life Sciences
Mantle-Cell Lymphoma Medicine & Life Sciences
Disease-Free Survival Medicine & Life Sciences
Follicular Lymphoma Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2006 2021

Research Output 2000 2019

35 Citations (Scopus)

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

ECHELON-2 Study Group, Jan 19 2019, In : The Lancet. 393, 10168, p. 229-240 12 p.

Research output: Contribution to journalArticle

Peripheral T-Cell Lymphoma
Drug Therapy

Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma

Khashab, T., Hagemeister, F., Romaguera, J. E., Fanale, M. A., Pro, B., McLaughlin, P., Rodriguez, M. A., Neelapu, S. S., Fayad, L., Younes, A., Feng, L., Vega, F., Kwak, L. W. & Samaniego, F., May 1 2019, In : British Journal of Haematology. 185, 4, p. 670-678 9 p.

Research output: Contribution to journalArticle

Non-Hodgkin's Lymphoma
Disease-Free Survival
Survival Rate
1 Citation (Scopus)

Novel therapies and approaches to relapsed/refractory HL beyond chemotherapy

Mina, A. A., Vakkalagadda, C. & Pro, B., Mar 2019, In : Cancers. 11, 3, 421.

Research output: Contribution to journalReview article

Open Access
Hodgkin Disease
Salvage Therapy
Drug Therapy
Stem Cells

Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry

Lansigan, F., Horwitz, S. M., Pinter-Brown, L. C., Rosen, S. T., Pro, B., Hsi, E. D., Federico, M., Gisselbrecht, C., Schwartz, M., Bellm, L. A., Acosta, M., Shustov, A. R., Advani, R. H., Feldman, T., Lechowicz, M. J., Smith, S. M., Tulpule, A., Craig, M. D., Greer, J. P., Kahl, B. S. & 5 others, Leach, J. W., Morganstein, N., Casulo, C., Park, S. I. & Foss, F. M., Jan 1 2019, In : Acta Haematologica.

Research output: Contribution to journalArticle

Peripheral T-Cell Lymphoma
T-Cell Lymphoma
1 Citation (Scopus)

Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry

Stuver, R. N., Khan, N., Schwartz, M., Acosta, M., Federico, M., Gisselbrecht, C., Horwitz, S. M., Lansigan, F., Pinter-Brown, L. C., Pro, B., Shustov, A. R., Foss, F. M. & Jain, S., Jun 1 2019, In : American Journal of Hematology. 94, 6, p. 641-649 9 p.

Research output: Contribution to journalArticle

Peripheral T-Cell Lymphoma
Combination Drug Therapy